Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: A randomized, controlled trial

Surgery

Volumn 141, Issue 4, 2007, Pages 501-510

  Bauhofer, Artur ^a   Plaul, Ulrike ^a   Torossian, Alexander ^a   Koller, Michael ^h   Stinner, Benno ^b   Celik, Ilhan ^a   Sitter, Helmut ^a   Greger, Bernd ^c   Middeke, Martin ^a   Schein, Moshe ^d   Wyatt, Jeremy ^e   Nyström, Per Olof ^f   Hartung, Thomas ^g   Rothmund, Matthias ^a   Lorenz, Wilfried ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Clinic of Visceral Thorax and Vascular Surgery   (Germany)

^c Clinic of Visceral   (Germany)

^d MARSHFIELD CLINIC   (United States)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f STOCKHOLM UNIVERSITY   (Sweden)

^g UNIVERSITY OF KONSTANZ   (Germany)

^h UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CELLULAR PARAMETERS; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; COST BENEFIT ANALYSIS; DEATH; DOUBLE BLIND PROCEDURE; FAMILY LIFE; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL PARAMETERS; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; ORGANIZATION; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESEARCH; SOCIAL INTERACTION; STATISTICAL SIGNIFICANCE; STRUCTURED INTERVIEW; TIME; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; COLECTOMY; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FILGRASTIM; HEMATOLOGIC AGENTS; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS;

EID: 33947385015     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2006.09.004     Document Type: Article

References (41)

1. Grimshaw J.M., and Russell I.T. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 342 (1993) 1317-1321
2. Kurz A., Sessler D.I., Lenhardt R., and The Study of Wound Infection and Temperature Group. Perioperative normothermia to reduce the incidence of surgical- wound infection and shorten hospitalization. N Eng J Med 334 (1996) 1209-1215
3. Beale R.J., Bryg D.J., and Bihari D.J. Immunonutrition in the critically ill: a systematic review of clinical outcome. Crit Care Med 27 (1999) 2799-2805
4. Basse L., Hjort J.D., Billesbolle P., Werner M., and Kehlet H. A clinical pathway to accelerate recovery after colonic resection. Ann Surg 232 (2000) 51-57
5. Hartmann L.C., Tschetter L.K., Habermann T.M., Ebbert L.P., Johnson P.S., Mailliard J.A., et al. Granulocyte colony-stimulating factor in severe chemotherapy- induced afebrile neutropenia. N Engl J Med 336 (1997) 1776-1780
6. Lorenz W., Stinner B., Bauhofer A., Rothmund M., Celik I., Fingerhut A., et al. Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimum recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part one: Rationale and hypothesis. Inflamm Res 50 (2001) 115-122
7. Jones E.A., Bolyard A.A., and Dale D.C. Quality of life of patients with severe chronic neutropenia receiving long-term treatment with granulocyte colony-stimulating factor. JAMA 270 (1993) 1132-1133
8. Bauhofer A., Lorenz W., Stinner B., Rothmund M., Koller M., Sitter H., et al. Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimum recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part two: design of the study. Inflamm Res 50 (2001) 187-205
9. Esposito S. Immune system and surgical site infection. J Chemother 13 Spec No 1 (2001) 12-16
10. Stinner B., Bauhofer A., Lorenz W., Rothmund M., Plaul U., Torossian A., et al. Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimum recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part three: individual patient, complication algorithm and quality management. Inflamm Res 50 (2001) 233-248
11. Bauhofer A., Torossian A., Lorenz W., Middeke M., Plaul U., Schütz P., et al. Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis. World J Surg 28 (2004) 834-844
12. Bauhofer A., Stinner B., Kohlert F., Reckzeh B., Lorenz W., and Celik I. Granulocyte colony-stimulating factor but not peritoneal lavage increases survival rate after experimental abdominal contamination and infection. Br J Surg 89 (2002) 1457-1463
13. Murty M., Enker W.E., and Martz J. Current status of total mesorectal excision and autonomic nerve preservation in rectal cancer. Semin Surg Oncol 19 (2000) 321-328
14. Koller M., and Lorenz W. Quality of life: a deconstruction for clinicians. J R Soc Med 95 (2002) 481-488
15. Kopp I., Bauhofer A., and Koller M. Understanding quality of life in patients with colorectal cancer: comparison of data from a randomised controlled trial, a population based cohort study and the norm reference population. Inflamm Res 53 Suppl 2 (2004) S130-S135
16. McPeek B., Gasko M., and Mosteller F. Measuring outcome from anesthesia and operation. Theor Surg 1 (1986) 2-9
17. Lorenz W., Duda D., Dick W., Sitter H., Doenicke A., Black A., et al. Incidence and clinical importance of perioperative histamine release: randomised study of volume loading and antihistamines after induction of anaesthesia. Lancet 343 (1994) 933-940
18. Marcus R., Peritz E., and Gabriel K. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63 (1976) 655-660
19. Moher D., Schulz K.F., and Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357 (2001) 1191-1194
20. Vironen J.H., Halme L., Sainio P., Kyllonen L.E., Scheinin T., Husa A.I., et al. New approaches in the management of rectal carcinoma result in reduced local recurrence rate and improved survival. Eur J Surg 168 (2002) 158-164
21. Lorenz W., Troidl H., Solomkin J.S., Nies C., Sitter H., Koller M., et al. Second step: testing - outcome measurements. World J Surg 23 (1999) 768-780
22. Elting L.S., and Cantor S.B. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer 10 (2002) 189-196
23. Poeze M., Froon A.H., Ramsay G., Buurman W.A., Greve J.W., and TCV-309 Septic Shock Study Group. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. Shock 14 (2000) 421-428
24. Rublee D., Opal S.M., Schramm W., Keinecke H.O., and Knaub S. Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial. Crit Care 6 (2002) 349-356
25. Bauhofer A., Lorenz W., Koller M., Menke H., Sessler D.I., Sitter H., et al. Evaluation of the McPeek outcome score in three trials. Langenbeck's Arch Surg 391 (2006) 418-427
26. Lyman G.H., and Kuderer N.M. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 62 Suppl 1 (2002) 65-78
27. Sackett D.L., Straus S.E., Richardson S.W., Rosenberg W., and Haynes R.B. Evidence based medicine. How to practice and teach EBM. 2nd ed. (2000), Churchill Livingstone, New York
28. Bauhofer A., Witte K., Lemmer B., Middeke M., Lorenz W., and Celik I. Quality of life in animals as a new outcome for surgical research: G-CSF as a quality of life improving factor. Eur Surg Res 34 (2002) 22-29
29. Konsman J.P., Parnet P., and Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 25 (2002) 154-159
30. Döcke W.D., Syrbe U., Meinecke A., Platzer C., Makki A., Asadullah K., et al. Improvement of monocyte function - a new therapeutic approach?. In: Reinhart K., Eyrich K., and Sprung C. (Eds). Sepsis - current perspectives in pathophysiology and therapy. 18 ed. (1994), Springer-Verlag, Germany 473-500
31. Schneider C., von Aulock S., Zedler S., Schinkel C., Hartung T., and Faist E. Perioperative recombinant human granulocyte colony-stimulating factor (filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 239 (2004) 75-81
32. Schaefer H., Engert A., Grass G., Mansmann G., Wassmer G., Hubel K., et al. Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial. Ann Surg 240 (2004) 68-75
33. Gough A., Clapperton M., Rolando N., and Foster A.V.M. Granulocyte-colony-stimulating factor in diabetic foot infection. Lancet 351 (1998) 70
34. Yonem A., Cakir B., Guler S., Azal O.O., and Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 3 (2001) 332-337
35. Kuritzkes D.R. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 30 (2000) 256-260
36. Weiss M., Gross-Weege W., Schneider M., Neidhardt H., Liebert S., Mirow N., et al. Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care 10 (1995) 21-26
37. Stephens D.P., Fisher D.A., and Currie B.J. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 32 (2002) 143-148
38. Nelson S., Heyder A.M., Stone J., Bergeron M.G., Daugherty S., Peterson G., et al. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 182 (2000) 970-973
39. Uyl-de Groot C.A., Hartog J.G., Derksen J.G., Symons E.A., Buijt I., van d V., et al. Cost-effectiveness and quality of life of granulocyte-colony stimulating factor (filgrastim) after radical vulvectomy and bilateral inguino-femoral lymphadenectomy: results of a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 114 (2004) 77-82
40. Lyman G.H., Kuderer N.M., and Balducci L. Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol 9 (2002) 207-214
41. Bohlius J., Reiser M., Schwarzer G., and Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev (2004) CD003189